Net Income (Loss) Attributable to Parent in USD of IGC Pharma, Inc. from Q2 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
IGC Pharma, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from Q2 2010 to Q3 2025.
  • IGC Pharma, Inc. Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2025 was -$1,821,000.000, a 6.06% decline year-over-year.
  • IGC Pharma, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2025 was -$6,447,000.000, a 48.7% increase year-over-year.
  • IGC Pharma, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$7,122,000.000, a 45.2% increase from 2023.
  • IGC Pharma, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$13,000,000.000, a 13% decline from 2022.
  • IGC Pharma, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$11,506,000.000, a 23.4% increase from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

IGC Pharma, Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$6,447,000 -$1,821,000 -$104,000 -6.1% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025
Q2 2025 -$6,343,000 -$1,599,000 +$779,000 +32.8% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025
Q1 2025 -$7,122,000 -$1,198,000 +$1,687,000 +58.5% 01 Jan 2025 31 Mar 2025 10-K 27 Jun 2025
Q4 2024 -$8,809,000 -$1,829,000 +$3,760,000 +67.3% 01 Oct 2024 31 Dec 2024 10-Q 14 Feb 2025
Q3 2024 -$12,569,000 -$1,717,000 +$734,000 +29.9% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025
Q2 2024 -$13,303,000 -$2,378,000 -$303,000 -14.6% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025
Q1 2024 -$13,000,000 -$2,885,000 +$1,145,000 +28.4% 01 Jan 2024 31 Mar 2024 10-K 27 Jun 2025
Q4 2023 -$14,145,000 -$5,589,000 -$3,340,000 -1.5% 01 Oct 2023 31 Dec 2023 10-Q 14 Feb 2025
Q3 2023 -$10,805,000 -$2,451,000 -$9,000 -0.37% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024
Q2 2023 -$10,796,000 -$2,075,000 +$710,000 +25.5% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024
Q1 2023 -$11,506,000 -$4,030,000 +$2,473,000 +38% 01 Jan 2023 31 Mar 2023 10-K 24 Jun 2024
Q4 2022 -$13,979,000 -$2,249,000 +$132,000 +5.5% 01 Oct 2022 31 Dec 2022 10-Q 14 Feb 2024
Q3 2022 -$14,111,000 -$2,442,000 +$1,902,000 +43.8% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023
Q2 2022 -$16,013,000 -$2,785,000 -$997,000 -55.8% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023
Q1 2022 -$15,016,000 -$6,503,000 -$3,554,000 -1.2% 01 Jan 2022 31 Mar 2022 10-K 07 Jul 2023
Q4 2021 -$11,462,000 -$2,381,000 -$58,000 -2.5% 01 Oct 2021 31 Dec 2021 10-Q 14 Feb 2023
Q3 2021 -$11,404,000 -$4,344,000 -$2,687,000 -1.6% 01 Jul 2021 30 Sep 2021 10-Q 01 Nov 2022
Q2 2021 -$8,717,000 -$1,788,000 +$94,000 +5% 01 Apr 2021 30 Jun 2021 10-Q 05 Aug 2022
Q1 2021 -$8,811,000 -$2,949,000 +$205,000 +6.5% 01 Jan 2021 31 Mar 2021 10-K 23 Jun 2022
Q4 2020 -$9,016,000 -$2,323,000 -$720,000 -44.9% 01 Oct 2020 31 Dec 2020 10-Q 10 Feb 2022
Q3 2020 -$8,296,000 -$1,657,000 -$478,000 -40.5% 01 Jul 2020 30 Sep 2020 10-Q 29 Oct 2021
Q2 2020 -$7,818,000 -$1,882,000 -$503,000 -36.5% 01 Apr 2020 30 Jun 2020 10-Q 11 Aug 2021
Q1 2020 -$7,315,000 -$3,154,000 -$1,576,000 -99.9% 01 Jan 2020 31 Mar 2020 10-K 14 Jun 2021
Q4 2019 -$5,739,000 -$1,603,000 -$455,000 -39.6% 01 Oct 2019 31 Dec 2019 10-Q 16 Feb 2021
Q3 2019 -$5,284,000 -$1,179,000 -$320,000 -37.3% 01 Jul 2019 30 Sep 2019 10-Q 20 Nov 2020
Q2 2019 -$4,964,000 -$1,379,000 -$867,000 -1.7% 01 Apr 2019 30 Jun 2019 10-Q 19 Aug 2020
Q1 2019 -$4,097,000 -$1,578,000 -$1,060,722 -2.1% 01 Jan 2019 31 Mar 2019 10-K 13 Jul 2020
Q4 2018 -$3,036,278 -$1,148,000 -$615,419 -1.2% 01 Oct 2018 31 Dec 2018 10-Q 10 Feb 2020
Q3 2018 -$2,420,859 -$859,000 -$555,000 -1.8% 01 Jul 2018 30 Sep 2018 10-Q 06 Nov 2019
Q2 2018 -$1,865,859 -$512,000 -$79,859 -18.5% 01 Apr 2018 30 Jun 2018 10-Q 09 Aug 2019
Q1 2018 -$1,786,000 -$517,278 +$270,984 +34.4% 01 Jan 2018 31 Mar 2018 10-K 14 Jun 2019
Q4 2017 -$2,056,984 -$532,581 -$421,020 -3.8% 01 Oct 2017 31 Dec 2017 10-Q 20 Feb 2018
Q3 2017 -$1,635,964 -$304,000 +$279,871 +47.9% 01 Jul 2017 30 Sep 2017 10-Q 16 Oct 2018
Q2 2017 -$1,915,835 -$432,141 -$48,575 -12.7% 01 Apr 2017 30 Jun 2017 10-Q 03 Aug 2018
Q1 2017 -$1,867,260 -$788,262 +$610,910 +43.7% 01 Jan 2017 31 Mar 2017 10-K 21 Jun 2018
Q4 2016 -$2,478,170 -$111,561 +$291,439 +72.3% 01 Oct 2016 31 Dec 2016 10-Q 20 Feb 2018
Q3 2016 -$2,769,609 -$583,871 +$39,502 +6.3% 01 Jul 2016 30 Sep 2016 10-Q 17 Nov 2017
Q2 2016 -$2,809,111 -$383,566 -$867 -0.23% 01 Apr 2016 30 Jun 2016 10-Q 18 Aug 2017
Q1 2016 -$2,808,244 -$1,399,172 +$536,069 +27.7% 01 Jan 2016 31 Mar 2016 10-K 14 Jul 2017
Q4 2015 -$3,344,313 -$403,000 +$187,114 +31.7% 01 Oct 2015 31 Dec 2015 10-Q 21 Feb 2017
Q3 2015 -$3,531,427 -$623,373 +$264,026 +29.8% 01 Jul 2015 30 Sep 2015 10-Q 21 Nov 2016
Q2 2015 -$3,795,453 -$382,699 +$818,730 +68.1% 01 Apr 2015 30 Jun 2015 10-Q 16 Aug 2016
Q1 2015 -$4,614,183 -$1,935,241 -$471,798 -32.2% 01 Jan 2015 31 Mar 2015 10-K 14 Jul 2016
Q4 2014 -$4,142,385 -$590,114 -$279,638 -90.1% 01 Oct 2014 31 Dec 2014 10-Q 16 Feb 2016
Q3 2014 -$3,862,747 -$887,399 -$272,212 -44.2% 01 Jul 2014 30 Sep 2014 10-Q 13 Nov 2015
Q2 2014 -$3,590,535 -$1,201,429 -$567,942 -89.7% 01 Apr 2014 30 Jun 2014 10-Q 14 Aug 2015
Q1 2014 -$3,022,593 -$1,463,443 +$428,772 +22.7% 01 Jan 2014 31 Mar 2014 10-K 14 Jul 2015
Q4 2013 -$3,451,365 -$310,476 -$621,368 -2% 01 Oct 2013 31 Dec 2013 10-Q 12 Feb 2015
Q3 2013 -$2,829,997 -$615,187 -$472,479 -3.3% 01 Jul 2013 30 Sep 2013 10-Q 13 Nov 2014
Q2 2013 -$2,357,518 -$633,487 -$105,171 -19.9% 01 Apr 2013 30 Jun 2013 10-Q 14 Aug 2014
Q1 2013 -$2,252,347 -$1,892,215 +$2,299,879 +54.9% 01 Jan 2013 31 Mar 2013 10-K 15 Jul 2014
Q4 2012 -$4,552,226 $310,892 +$2,212,267 01 Oct 2012 31 Dec 2012 10-Q 14 Feb 2014
Q3 2012 -$6,764,493 -$142,708 +$646,545 +81.9% 01 Jul 2012 30 Sep 2012 10-Q 08 Nov 2013
Q2 2012 -$7,411,038 -$528,316 +$340,887 +39.2% 01 Apr 2012 30 Jun 2012 10-Q 16 Aug 2013
Q1 2012 -$7,751,925 -$4,192,094 +$12,852,361 +75.4% 01 Jan 2012 31 Mar 2012 10-K 15 Jul 2014
Q4 2011 -$20,604,286 -$1,901,375 -$152,357 -8.7% 01 Oct 2011 31 Dec 2011 10-Q 13 Feb 2013
Q3 2011 -$20,451,929 -$789,253 +$67,007 +7.8% 01 Jul 2011 30 Sep 2011 10-Q 14 Nov 2012
Q2 2011 -$20,518,936 -$869,203 -$278,029 -47% 01 Apr 2011 30 Jun 2011 10-Q/A 21 Aug 2012
Q1 2011 -$20,240,907 -$17,044,455 01 Jan 2011 31 Mar 2011 10-K 16 Jul 2012
Q4 2010 -$1,749,018 01 Oct 2010 31 Dec 2010 10-Q 16 Feb 2012
Q3 2010 -$856,260 01 Jul 2010 30 Sep 2010 10-Q 18 Nov 2011
Q2 2010 -$591,174 01 Apr 2010 30 Jun 2010 10-Q 18 Aug 2011

IGC Pharma, Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$7,122,000 +$5,878,000 +45.2% 01 Apr 2024 31 Mar 2025 10-K 27 Jun 2025
2023 -$13,000,000 -$1,494,000 -13% 01 Apr 2023 31 Mar 2024 10-K 27 Jun 2025
2022 -$11,506,000 +$3,510,000 +23.4% 01 Apr 2022 31 Mar 2023 10-K 24 Jun 2024
2021 -$15,016,000 -$6,205,000 -70.4% 01 Apr 2021 31 Mar 2022 10-K 07 Jul 2023
2020 -$8,811,000 -$1,496,000 -20.5% 01 Apr 2020 31 Mar 2021 10-K 23 Jun 2022
2019 -$7,315,000 -$3,218,000 -78.5% 01 Apr 2019 31 Mar 2020 10-K 14 Jun 2021
2018 -$4,097,000 -$2,311,000 -1.3% 01 Apr 2018 31 Mar 2019 10-K 13 Jul 2020
2017 -$1,786,000 +$81,260 +4.4% 01 Apr 2017 31 Mar 2018 10-K 14 Jun 2019
2016 -$1,867,260 +$940,984 +33.5% 01 Apr 2016 31 Mar 2017 10-K 21 Jun 2018
2015 -$2,808,244 +$1,805,939 +39.1% 01 Apr 2015 31 Mar 2016 10-K 14 Jul 2017
2014 -$4,614,183 -$1,591,590 -52.7% 01 Apr 2014 31 Mar 2015 10-K 14 Jul 2016
2013 -$3,022,593 -$770,246 -34.2% 01 Apr 2013 31 Mar 2014 10-K 14 Jul 2015
2012 -$2,252,347 +$5,499,578 +70.9% 01 Apr 2012 31 Mar 2013 10-K 15 Jul 2014
2011 -$7,751,925 +$12,488,982 +61.7% 01 Apr 2011 31 Mar 2012 10-K 15 Jul 2014
2010 -$20,240,907 01 Apr 2010 31 Mar 2011 10-K 16 Jul 2012
* An asterisk sign (*) next to the value indicates that the value is likely invalid.